BidaskClub upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP) from a sell rating to a hold rating in a research note issued to investors on Friday.

A number of other brokerages also recently weighed in on CRBP. Cantor Fitzgerald set a $28.00 target price on Corbus Pharmaceuticals and gave the company an overweight rating in a report on Thursday, December 14th. Noble Financial reiterated a buy rating on shares of Corbus Pharmaceuticals in a report on Friday, December 15th. Finally, ValuEngine downgraded Corbus Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Corbus Pharmaceuticals currently has an average rating of Hold and a consensus price target of $25.00.

Corbus Pharmaceuticals (CRBP) opened at $7.10 on Friday. The firm has a market capitalization of $403.32, a PE ratio of -11.45 and a beta of 175.11. Corbus Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $10.50.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. equities research analysts expect that Corbus Pharmaceuticals will post -0.6 earnings per share for the current year.

In other news, Director David P. Hochman purchased 10,000 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was acquired at an average price of $7.08 per share, with a total value of $70,800.00. Following the purchase, the director now owns 459,500 shares in the company, valued at approximately $3,253,260. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David P. Hochman purchased 5,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $6.90 per share, with a total value of $34,500.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 25,336 shares of company stock valued at $175,632. 11.90% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System bought a new stake in shares of Corbus Pharmaceuticals in the 3rd quarter valued at approximately $108,000. Yellowstone Partners LLC bought a new stake in shares of Corbus Pharmaceuticals in the 3rd quarter valued at approximately $110,000. Credit Suisse AG bought a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at approximately $157,000. Voya Investment Management LLC bought a new stake in shares of Corbus Pharmaceuticals in the 2nd quarter valued at approximately $125,000. Finally, Capital Fund Management S.A. bought a new stake in shares of Corbus Pharmaceuticals in the 2nd quarter valued at approximately $130,000. 27.84% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/01/02/corbus-pharmaceuticals-crbp-upgraded-at-bidaskclub.html.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.